Four years and $145M+ lat­er, No­vo Nordisk hands back the rights to hor­mone growth de­fi­cien­cy test

Af­ter chang­ing hands a cou­ple of times, Aeter­na Zen­taris’ adult growth hor­mone de­fi­cien­cy (AGHD) test Macrilen is re­turn­ing to its orig­i­nal de­vel­op­er as No­vo Nordisk …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER